Product Pipeline for New Pharmaceutical Drugs

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib (JAK1 Inhibitor):  Atopic Dermatitis 
  • Braftovi® (encorafinib)  + Erbitux® (cetuximab):  1st line BRAF-mutant Metastatic Colorectal Cancer 
  • Braftovi® (encorafinib) + Mektovi® (binimetinib) + Keytruda® (pembrolizumab):  BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
  • COVID-19 Vaccine:  COVID-19 Infection (in collaboration with BioNTech)
  • Fidanacogene elaparvovec (PF-06838435) (Gene Therapy, coagulation factor IX):  Hemophilia
  • Fordadistrogene movaparvovec (PF-06939926) (Gene Therapy):  Duchenne Muscular Dystrophy
  • Giroctocogene fitelparvovec (PF-07055480) (Gene Therapy, coagulation factor VIII):  Hemophilia
  • Marstacimab (PF-06741086) (Tissue Factor Pathway Inhibitor):  Hemophilia
  • Prophylactic Vaccine:  Clostridioides difficile infection
  • Prophylactic Vaccine:  Invasive and Non-Invasive Pneumococcal infections (adult, pediatric) 
  • Prophylactic Vaccine:  Meningococcal Infections (adolescent and young adults)
  • Prophylactic Vaccine:  Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
  • Relugolix combination: Uterine Fibroids, Endometriosis
  • Ritlecitinib (JAK3/TEC Inhibitor):  Alopecia Areata 
  • Sasanlimab (PF-06801591) + BCG:  Non-Muscle-Invasive Bladder Cancer
  • Somatrogon (PF-06836922):  Growth Hormone Deficiency (adult, pediatric)
  • Talzenna® (talazoparib) + Xtandi® (enzalutamide):  1st Line Metastatic Castration-Resistant Prostate Cancer 
  • Tanezumab:  Chronic Pain due to Moderate-to-Severe Osteoarthritis; Cancer Pain
  • Xtandi® (enzalutamide):  Non-metastatic High-Risk Castration Sensitive Prostate Cancer

Pipeline Snapshot as of May 4, 2021

  • Discovery Projects
  • Phase 1
    30
  • Phase 2
    38
  • Phase 3
    22
  • Registration
    10
  • Total100
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-06482077
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH, FAST TRACK - U.S.; E.U.)
Project advanced
Registration New Molecular Entity Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
Go to clinical trial
COVID-19 Infection (in collaboration with BioNTech)(FAST TRACK, U.S.; E.U.) Registration New Molecular Entity Vaccine
TicoVac
Therapeutic Area:
Vaccines
Phase:Registration
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Tick-borne encephalitis (TBE) (U.S.)
Project advanced
Registration New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary Clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (pediatric) (BREAKTHROUGH, FAST TRACK) Phase 3 Product Enhancement Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY Meningococcal Infections (adolescent and young adults) Phase 3 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection (maternal) (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-07307405
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Lyme disease (FAST TRACK) Phase 2 New Molecular Entity Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (maternal)
Project advanced
Phase 2 Product Enhancement Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (children 2 to 11 years of age)
Project advanced
Phase 2 Product Enhancement Vaccine
PF-07302048 (Covid-19 Vx)
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in collaboration with BioNTech) (infants 6 months to <24 months)
Project advanced
Phase 2 Product Enhancement Vaccine
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (E.U.)
Project advanced
Registration Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Metastatic Castration Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 kinase inhibitor
Go to clinical trial
ER+/HER2+ Metastatic Breast Cancer(PATINA) Phase 3 Product Enhancement Small Molecule
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic